Back to Peptides

Kisspeptin

Emerging

KISS1 Gene Product | Reproductive Neuropeptide

Dose 100-200 mcg per injection
Frequency Single dose for testing, or 2-3 times weekly (NEVER daily - causes desensitization)
Cycle 2-4 weeks
Storage Lyophilized: Room temperature. Reconstituted: 2-8°C. KP-10: use within 7 days. KP-54: use within 14 days
Accumulation Plotter

Kisspeptin acts as a master regulator of the reproductive system, stimulating GnRH neurons essential for puberty, fertility, and reproductive function.

Mechanism of Action

Binds to GPR54/KISS1R receptors on hypothalamic GnRH neurons, triggering pulsatile GnRH release, which stimulates pituitary LH/FSH secretion and gonadal steroid production.

Key Benefits

  • Potent reproductive hormone stimulation (LH/FSH)
  • Restoration of natural testosterone production
  • Fertility enhancement
  • Sexual function support
  • Hypogonadism treatment potential
Molecular Weight
1,213.42 Da (KP-10) / 6,087 Da (KP-54)
Chain Length
10-54 amino acids
Type
Neuropeptide family (RFamide)
Amino Acid Sequence
One-letter: ??NWNSFGLRF?
H₂N
H
? 1
O ‖ C
N
H
? 2
O ‖ C
N
N 3
O ‖ C
N
W 4
O ‖ C
N
N 5
O ‖ C
N
S 6
O ‖ C
N
F 7
O ‖ C
N
H
G 8
O ‖ C
N
L 9
O ‖ C
N
R 10
O ‖ C
N
F 11
O ‖ C
N
H
? 12
COOH
Kis
1

Kisspeptin

Position 1

10:
2

10: Tyr

Position 2

Asn
3

Asparagine

Position 3

Trp
4

Tryptophan

Position 4

Asn
5

Asparagine

Position 5

Ser
6

Serine

Position 6

Phe
7

Phenylalanine

Position 7

Gly
8

Glycine

Position 8

Leu
9

Leucine

Position 9

Arg
10

Arginine

Position 10

Phe
11

Phenylalanine

Position 11

NH2
12

NH2

Position 12

N-terminus C-terminus
Hydrophobic
Polar
Positive (+)
Negative (-)
Modified

Reproductive

  • Hypogonadotropic Hypogonadism

    Restores reproductive hormone secretion in functional or congenital cases by stimulating dormant GnRH axis.

  • IVF Ovulation Trigger

    Triggers oocyte maturation with 45% live birth rate and zero severe OHSS cases; safer than hCG.

  • Hypothalamic Amenorrhea

    Restores reproductive hormone pulsatility in women with hypothalamic amenorrhea.

Sexual Function

  • Hypoactive Sexual Desire Disorder (Men)

    Modulates sexual brain processing; increases penile tumescence by 56% vs placebo.

  • Hypoactive Sexual Desire Disorder (Women)

    Modulates sexual and attraction brain processing; increases self-reported sexiness.

Metabolic

  • Energy Metabolism

    Preclinical evidence suggests influence on energy expenditure and activity levels.

Standard administration route; allows precise dosing and rapid hormone stimulation.

GoalDoseFrequencyRoute
Gonadotropin stimulation100-200mcgSingle dose or 2-3x weeklySubQ
Fertility support0.4-1.0 nmol/kg (50-150mcg)As directed by physicianSubQ (KP-54)
Sexual function (clinical)1 nmol/kg/h75-minute IV infusionIV infusion

Reconstitution Instructions

Materials Needed:
  • Bacteriostatic water (BAC water)
  • Insulin syringes (0.5-1 mL)
  • Alcohol swabs
  • Sterile work surface
  1. 1 Clean work area and hands thoroughly with alcohol
  2. 2 Calculate required BAC water volume
  3. 3 Draw calculated water into syringe
  4. 4 Inject slowly down vial side (not directly onto powder)
  5. 5 Gently swirl until dissolved (never shake)
  6. 6 Store in refrigerator at 2-8°C
  7. 7 Use within 7 days for KP-10; 14 days for KP-54
GnRH

Kisspeptin stimulates GnRH release; works upstream in reproductive axis.

synergistic
HCG

Serves as potentially safer alternative for IVF ovulation triggering.

compatible
Testosterone

Restores natural testosterone production through LH stimulation.

compatible
Estrogen

Kisspeptin function modulated by sex steroids in feedback loops.

compatible
Hours 2-5

LH surge peaks at 3-5x baseline

Hours 12-14

LH returns to baseline

Days 1-2

Testosterone/estradiol increase in response to LH

Weeks 2-4

Potential improvements in sexual function and libido

Common Side Effects

  • Minimal acute side effects reported
  • Potential mild cardiovascular effects

Stop Signs - Discontinue if:

  • Ovarian hyperstimulation signs: severe pelvic pain, bloating, nausea
  • Chest pain or cardiovascular symptoms
  • Severe headaches or visual disturbances
  • Persistent injection site reactions

Contraindications

  • Not recommended during pregnancy or breastfeeding
  • Caution with cardiovascular disease history
  • Daily dosing causes receptor desensitization

Good Signs

  • White, fluffy powder; proper freeze-drying indicated
  • Clear solution after reconstitution; no particles or cloudiness
  • Protected from light in amber/opaque vials

Warning Signs

  • Slight compaction acceptable if dissolves completely with gentle swirling

Bad Signs

  • Discoloration or yellowing indicates oxidation/degradation
  • Cloudy after reconstitution indicates degradation or contamination
  • Kisspeptin for Hypoactive Sexual Desire Disorder in Men
    (2023)

    Modulated sexual brain activity; increased penile tumescence by 56% vs placebo. JAMA Network Open.

  • Kisspeptin for HSDD in Women
    (2022)

    Modulated sexual and attraction processing; increased self-reported sexiness. JAMA Network Open.

  • Kisspeptin as IVF Ovulation Trigger
    (2017)

    45% live birth rate with zero severe OHSS; safer than hCG trigger. Journal of Clinical Investigation.

  • Intranasal Kisspeptin Administration
    (2025)

    Non-invasive delivery with rapid gonadotropin stimulation; stable 60-day formulation. eBioMedicine.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.